Verge Genomics
+44%
est. 2Y upside i
We use human data and AI to develop better drugs faster.
Rank
#1092
Sector
Biotechnology
Est. Liquidity
~2Y
Data Quality
Data: LowVerge Genomics is a high-risk opportunity for a job candidate.
Last updated: July 19, 2026
Strategic partnership with big pharma or AI platform deal drives multiple expansion to 7x revenue, yielding $686M exit. Common equity returns 270% net of 20% dilution.
Gradual recovery and licensing revenue stabilize at $98M, multiple converges to 4.5x. Exit at $441M nets common 89% return after dilution.
Continued pipeline failures and cash burn lead to multiple compression to 2x revenue; exit at $196M barely covers liquidation preference, common loses 93% (nearly wiped out).
Preference Stack Risk
severeFunding Intensity
54%Total funding of $159M exceeds 50% of current valuation, meaning common stock is deeply in the money only if exit exceeds $159M.
Dilution Risk
highWith high burn and recent layoffs, a capital raise is likely within 2 years, diluting current holders by ~20%.
Secondary Liquidity
noneNo secondary market activity reported.
Questions to Ask at the Interview
Strategic questions based on Verge Genomics's data — designed to show you've done your homework.
- 1
“How would you approach rebuilding the pipeline given the recent trial failure?”
- 2
“What is the revenue model for the AI platform and how can it scale without a marketed drug?”
- 3
“How does the equity structure (preferred stack) affect employee common stock value, and what is the expected path to liquidity?”
Community
Valuation Sentiment
Our model estimates +44% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.